CN109674754B - 一种氟哌噻吨美利曲辛药物组合物及其制剂 - Google Patents
一种氟哌噻吨美利曲辛药物组合物及其制剂 Download PDFInfo
- Publication number
- CN109674754B CN109674754B CN201910024441.8A CN201910024441A CN109674754B CN 109674754 B CN109674754 B CN 109674754B CN 201910024441 A CN201910024441 A CN 201910024441A CN 109674754 B CN109674754 B CN 109674754B
- Authority
- CN
- China
- Prior art keywords
- flupentixol
- melitracen
- hydrochloride
- granules
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004794 melitracen Drugs 0.000 title claims abstract description 190
- GWWLWDURRGNSRS-UHFFFAOYSA-N melitracen Chemical compound C1=CC=C2C(=CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 GWWLWDURRGNSRS-UHFFFAOYSA-N 0.000 title claims abstract description 141
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 59
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 11
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 title claims description 6
- 229960002419 flupentixol Drugs 0.000 title abstract description 153
- 238000002360 preparation method Methods 0.000 title abstract description 58
- NJMYODHXAKYRHW-BLLMUTORSA-N 2-[4-[(3e)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1CC\C=C/1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2\1 NJMYODHXAKYRHW-BLLMUTORSA-N 0.000 claims abstract description 206
- 229940050842 flupentixol hydrochloride Drugs 0.000 claims abstract description 59
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 43
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 39
- 239000003826 tablet Substances 0.000 claims description 88
- 239000008187 granular material Substances 0.000 claims description 87
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical group CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 21
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 21
- 239000000945 filler Substances 0.000 claims description 16
- 239000000314 lubricant Substances 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 13
- NECXFGBJNUZGBH-RZFZGDDESA-N 3-(10,10-dimethylanthracen-9-ylidene)-n,n-dimethylpropan-1-amine;2-[4-[(3e)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol Chemical compound C1=CC=C2C(=CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1.C1CN(CCO)CCN1CC\C=C/1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2\1 NECXFGBJNUZGBH-RZFZGDDESA-N 0.000 abstract description 7
- 239000012535 impurity Substances 0.000 abstract description 7
- ITUIINCSZOTHJI-UHFFFAOYSA-N 1-(trifluoromethyl)thioxanthen-9-one Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C=CC=C2C(F)(F)F ITUIINCSZOTHJI-UHFFFAOYSA-N 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 2
- RADLXCPDUXFGFF-UHFFFAOYSA-N Melitracen hydrochloride Chemical compound Cl.C1=CC=C2C(=CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 RADLXCPDUXFGFF-UHFFFAOYSA-N 0.000 description 49
- 235000006708 antioxidants Nutrition 0.000 description 38
- 239000000243 solution Substances 0.000 description 37
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 30
- 229940016286 microcrystalline cellulose Drugs 0.000 description 30
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 30
- 239000008108 microcrystalline cellulose Substances 0.000 description 30
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 29
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 29
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 29
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- 239000002245 particle Substances 0.000 description 28
- 238000003756 stirring Methods 0.000 description 28
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 25
- 238000002156 mixing Methods 0.000 description 24
- 229960001375 lactose Drugs 0.000 description 23
- 239000008101 lactose Substances 0.000 description 23
- 238000001035 drying Methods 0.000 description 21
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 19
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 18
- 238000009775 high-speed stirring Methods 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 238000010008 shearing Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000007888 film coating Substances 0.000 description 13
- 238000009501 film coating Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 239000008213 purified water Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000853 adhesive Substances 0.000 description 10
- 230000001070 adhesive effect Effects 0.000 description 10
- 229960004977 anhydrous lactose Drugs 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 9
- 235000010388 propyl gallate Nutrition 0.000 description 9
- 239000000473 propyl gallate Substances 0.000 description 9
- 229940075579 propyl gallate Drugs 0.000 description 9
- 239000013558 reference substance Substances 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 5
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 5
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- 229940057948 magnesium stearate Drugs 0.000 description 4
- -1 melitracen compound Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000012088 reference solution Substances 0.000 description 4
- 238000005096 rolling process Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010812 external standard method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000011056 performance test Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical group [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- RAUSRFQDDOIORP-UHFFFAOYSA-N 1-(trifluoromethyl)thioxanthen-9-one hydrochloride Chemical compound FC(F)(F)C1=CC=CC=2SC3=CC=CC=C3C(C12)=O.Cl RAUSRFQDDOIORP-UHFFFAOYSA-N 0.000 description 1
- GWFCYDIAPRIMLA-UHFFFAOYSA-N 10,10-dimethylanthracen-9-one Chemical compound C1=CC=C2C(C)(C)C3=CC=CC=C3C(=O)C2=C1 GWFCYDIAPRIMLA-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- IMOYOUMVYICGCA-UHFFFAOYSA-N 2-tert-butyl-4-hydroxyanisole Chemical group COC1=CC=C(O)C=C1C(C)(C)C IMOYOUMVYICGCA-UHFFFAOYSA-N 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical class C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- IGHQDWCUHJFFDG-UHFFFAOYSA-N CS1(C2=CC=CC=C2C(=O)C2=C1C=CC=C2)C Chemical compound CS1(C2=CC=CC=C2C(=O)C2=C1C=CC=C2)C IGHQDWCUHJFFDG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 101000889329 Conus textile Conotoxin tx5d Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- IOVDQEIIMOZNNA-MHKBYHAFSA-N cis-flupenthixol dihydrochloride Chemical compound Cl.Cl.C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 IOVDQEIIMOZNNA-MHKBYHAFSA-N 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000012494 forced degradation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- IOVDQEIIMOZNNA-UHFFFAOYSA-N hydron;2-[4-[3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol;dichloride Chemical compound Cl.Cl.C1CN(CCO)CCN1CCC=C1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 IOVDQEIIMOZNNA-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910001719 melilite Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910024441.8A CN109674754B (zh) | 2019-01-10 | 2019-01-10 | 一种氟哌噻吨美利曲辛药物组合物及其制剂 |
GB2111477.2A GB2595140B (en) | 2019-01-10 | 2019-12-13 | Flupentixol/melitracen pharmaceutical composition and preparation thereof |
PCT/CN2019/125211 WO2020143394A1 (zh) | 2019-01-10 | 2019-12-13 | 一种氟哌噻吨美利曲辛药物组合物及其制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910024441.8A CN109674754B (zh) | 2019-01-10 | 2019-01-10 | 一种氟哌噻吨美利曲辛药物组合物及其制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109674754A CN109674754A (zh) | 2019-04-26 |
CN109674754B true CN109674754B (zh) | 2021-10-08 |
Family
ID=66192951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910024441.8A Active CN109674754B (zh) | 2019-01-10 | 2019-01-10 | 一种氟哌噻吨美利曲辛药物组合物及其制剂 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN109674754B (zh) |
GB (1) | GB2595140B (zh) |
WO (1) | WO2020143394A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109771386B (zh) * | 2019-01-10 | 2021-10-08 | 广东赛烽医药科技有限公司 | 一种氟哌噻吨美利曲辛片剂及其制备方法 |
CN109674754B (zh) * | 2019-01-10 | 2021-10-08 | 广东赛烽医药科技有限公司 | 一种氟哌噻吨美利曲辛药物组合物及其制剂 |
CN112300119B (zh) * | 2019-08-02 | 2024-04-16 | 苏州恩华生物医药科技有限公司 | 美利曲辛与氟哌噻吨共晶及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101912397A (zh) * | 2010-04-30 | 2010-12-15 | H.隆德贝克有限公司 | 氟哌噻吨组合物 |
WO2012032360A2 (en) * | 2010-09-10 | 2012-03-15 | Helperby Therapeutics Limited | Novel use |
CN105663062A (zh) * | 2016-02-17 | 2016-06-15 | 南京卓泰医药科技有限公司 | 一种氟哌噻吨美利曲辛药物组合物及其制备方法 |
CN108362792A (zh) * | 2018-01-31 | 2018-08-03 | 成都倍特药业有限公司 | 一种氟哌噻吨美利曲辛复方药物杂质的检测方法、新的可识别杂质及更安全的复方药物 |
CN108498470A (zh) * | 2017-02-24 | 2018-09-07 | 重庆圣华曦药业股份有限公司 | 一种氟哌噻吨美利曲辛药物组合物及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2374450T1 (sl) * | 2010-04-06 | 2012-09-28 | Lundbeck & Co As H | Sestavki flupentiksola |
CN103877088A (zh) * | 2012-12-19 | 2014-06-25 | H.隆德贝克有限公司 | 一种安全性高的美利曲辛药物组合物 |
CN104288153B (zh) * | 2014-09-19 | 2019-10-29 | 四川海思科制药有限公司 | 一种氟哌噻吨美利曲辛药物组合物及其制备方法 |
CN109771386B (zh) * | 2019-01-10 | 2021-10-08 | 广东赛烽医药科技有限公司 | 一种氟哌噻吨美利曲辛片剂及其制备方法 |
CN109674754B (zh) * | 2019-01-10 | 2021-10-08 | 广东赛烽医药科技有限公司 | 一种氟哌噻吨美利曲辛药物组合物及其制剂 |
-
2019
- 2019-01-10 CN CN201910024441.8A patent/CN109674754B/zh active Active
- 2019-12-13 WO PCT/CN2019/125211 patent/WO2020143394A1/zh active Application Filing
- 2019-12-13 GB GB2111477.2A patent/GB2595140B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101912397A (zh) * | 2010-04-30 | 2010-12-15 | H.隆德贝克有限公司 | 氟哌噻吨组合物 |
WO2012032360A2 (en) * | 2010-09-10 | 2012-03-15 | Helperby Therapeutics Limited | Novel use |
CN105663062A (zh) * | 2016-02-17 | 2016-06-15 | 南京卓泰医药科技有限公司 | 一种氟哌噻吨美利曲辛药物组合物及其制备方法 |
CN108498470A (zh) * | 2017-02-24 | 2018-09-07 | 重庆圣华曦药业股份有限公司 | 一种氟哌噻吨美利曲辛药物组合物及其制备方法 |
CN108362792A (zh) * | 2018-01-31 | 2018-08-03 | 成都倍特药业有限公司 | 一种氟哌噻吨美利曲辛复方药物杂质的检测方法、新的可识别杂质及更安全的复方药物 |
Also Published As
Publication number | Publication date |
---|---|
CN109674754A (zh) | 2019-04-26 |
WO2020143394A1 (zh) | 2020-07-16 |
GB2595140B (en) | 2023-06-14 |
GB2595140A (en) | 2021-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2520288B1 (en) | Production method of solid preparation and the preparation produced by the method | |
CN109674754B (zh) | 一种氟哌噻吨美利曲辛药物组合物及其制剂 | |
CN107595784B (zh) | 他克莫司缓释药物组合物 | |
CN109771386B (zh) | 一种氟哌噻吨美利曲辛片剂及其制备方法 | |
CN113384581B (zh) | 一种包含促性腺激素释放激素拮抗剂的药物组合物 | |
CN114288257B (zh) | 一种马来酸氟伏沙明片剂及其制备方法 | |
EP3749286A1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
EP2050436A1 (en) | Pharmaceutical composition containing dutasteride | |
CN108066312B (zh) | 一种帕博西尼药物组合物及其制备方法 | |
CN112305107A (zh) | 磷酸二酯酶-4抑制剂阿普斯特组合物及质量检测方法 | |
CN102764254B (zh) | 一种左乙拉西坦药物组合物及其制备方法 | |
CN114917233B (zh) | 一种包含核苷类似物的药物组合物及其制备方法和应用 | |
CN115154431B (zh) | 一种硝酸甘油片剂及其制备方法 | |
CN113116892B (zh) | 含有瑞格列奈的药物组合物及其制备方法 | |
CN113209036B (zh) | 一种阿齐沙坦片及其制备方法和应用 | |
CN112245403B (zh) | 磷酸二酯酶-4抑制剂及其口服固体组合物 | |
CN114533691A (zh) | 一种阿普米司特片剂及其工业化制备方法 | |
CN108125918A (zh) | 依维莫司药物组合物 | |
CN103919780B (zh) | 镇静安眠制剂、其复方制剂、制备方法及药物组合物 | |
WO2024153130A1 (zh) | 一种包含并环化合物的药物组合物及其制备方法和应用 | |
CN113116833B (zh) | 一种比拉斯汀片剂及其制备方法 | |
CN112999176B (zh) | 一种阿昔替尼片剂 | |
CN112076163B (zh) | 一种醋酸巴多昔芬片的药物组合物及其制备方法 | |
CN108236609B (zh) | 一种gpr40激动剂药物组合物及其制备方法 | |
CN106667935A (zh) | 一种罗氟司特片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 510000 No.2 Jiaoyuan Road, Huangpu District, Guangzhou City, Guangdong Province Applicant after: GUANGDONG SCIENTIFIC FINDER PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Applicant after: HAINAN HUINENG PHARMACEUTICAL Co.,Ltd. Address before: 510000 room 2301, building 1, block 4, hailunburg Creative Park, 329 Yushan Road, Shatou street, Panyu District, Guangzhou City, Guangdong Province Applicant before: GUANGDONG SCIENTIFIC FINDER PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Applicant before: HAINAN HUINENG PHARMACEUTICAL Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |